Last updated on June 2018

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET


Brief description of study

The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.

Detailed Study Description

The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical. The specific objectives are:

  • To measure the dynamic uptake and washout of [18F]MNI- 958 in brain using positron emission tomography (PET) in patients with Alzheimer's disease, Progressive Supranuclear Palsy and healthy volunteers.
  • To measure blood metabolites of [18F]MNI-958 and perform kinetic modeling to assess its ability to measure tau protein in brain using the tracer plasma concentration or a reference region as indirect input.
  • To obtain test/retest reliability of the tracer binding parameters in patients with Alzheimer's disease, Progressive Supranuclear Palsy and healthy volunteers.
  • To acquire safety data following injection of [18F]MNI-958.

Clinical Study Identifier: NCT03545789

Contact Investigators or Research Sites near you

Start Over

Jennifer Madonia, MS, PA-C

Invicro
New Haven, CT United States
  Connect »